febuxostat推荐用量

The main ingredient is febuxostat, whose chemical name is 2-[(3-cyano-4-isobutoxy)phenyl]-4-methyl-5-thiazolecarboxylic acid. It is a xanthine oxidase (XO) inhibitor and is suitable for the long-term treatment of hyperuricemia with gout symptoms.

The recommended oral dose of febuxostat is 40 mg or 80 mg once daily.

The recommended starting dose of febuxostat is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl (approximately 360 µmol/L) after 2 weeks, it is recommended that the dose be increased to 80 mg once a day.

Food and antacid effects do not need to be considered when administering the drug.

Special groups:

Patients with hepatic impairment: Patients with mild or moderate hepatic impairment (Child-Pugh Class A, B) do not need to adjust the dose. The efficacy and safety of febuxostat have not been studied in patients with severe hepatic insufficiency (Child-Pugh class C). Therefore, febuxostat should be used with caution in these patients.

Patients with renal insufficiency: Patients with mild or moderate renal insufficiency (Clcr30-89 ml/min) do not need to adjust the dose. The recommended starting dose of febuxostat is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl after 2 weeks, it is recommended that the dose be increased to 80 mg once a day. There are insufficient study data in patients with severe renal insufficiency (Clcr <30ml/min), so febuxostat should be used with caution in these patients.

Uric acid level: 2 weeks after starting febuxostat treatment, it is possible to assess whether the serum uric acid level has reached the target value (less than 6 mg/dl).

Gout Attacks: Changing serum uric acid levels can lead to the activity of deposited urate, thus leading to gout attacks after initiation of administration of this product. It is recommended that when using this product, non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine should be administered at the same time to prevent gout attacks. It is recommended to take the medicine for at least 6 months to prevent acute attacks of gout.

If gout occurs during treatment with this drug, there is no need to discontinue the drug. Individual patients with gout should be treated accordingly.

Secondary hyperuricemia: There are no studies on the administration of this product to patients with secondary hyperuricemia (including organ transplant patients); its use (febuxostat) is not recommended in patients with increased urate production (e.g. malignant diseases and their treatment, Reye-Naphthalene syndrome).